Charles River upgraded by Evercore ISI with a new price target
$CRL
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Evercore ISI upgraded Charles River from In-line to Outperform and set a new price target of $170.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/23/2025 | $182.00 | Neutral → Buy | Redburn Atlantic |
| 5/14/2025 | $179.00 | Hold → Buy | TD Cowen |
| 5/8/2025 | $170.00 | In-line → Outperform | Evercore ISI |
| 3/21/2025 | $190.00 → $170.00 | Buy → Neutral | Goldman |
| 3/4/2025 | $155.00 → $175.00 | Sell → Neutral | Citigroup |
| 3/3/2025 | $188.00 | Sell → Neutral | Redburn Atlantic |
| 1/22/2025 | Outperform → Mkt Perform | William Blair | |
| 1/17/2025 | $250.00 → $185.00 | Buy → Neutral | UBS |
Redburn Atlantic upgraded Charles River from Neutral to Buy and set a new price target of $182.00
TD Cowen upgraded Charles River from Hold to Buy and set a new price target of $179.00
Evercore ISI upgraded Charles River from In-line to Outperform and set a new price target of $170.00
A solution for laboratories seeking to reduce single-use plastic waste Charles River Laboratories International, Inc. (NYSE:CRL) today announced a recycling program, developed in partnership with international recycling leader TerraCycle®, to give new life to single-use plastic cartridges. This groundbreaking collaboration offers users of Charles River's Endosafe® bacterial endotoxin testing (BET) cartridge technology an avenue to responsibly recycle single-use plastic cartridges used specifically for routine water testing. The cartridge recycling program reaffirms Charles River's ongoing commitment to minimize the Company's environmental footprint and offer a service to assist clients in
Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 4th, at 10:30 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available fo
Charles River Laboratories International, Inc. (NYSE:CRL) and CHDI Foundation, Inc., today announced an extension of their ongoing drug discovery partnership into the foreseeable future. The organizations began working together in 2005 to expedite therapeutic development for Huntington's disease (HD), a genetic neurological disorder that causes the progressive dysfunction of nerve cells in the brain. The extension in 2025, marking the 20-year anniversary of the collaboration, will allow more flexible activity across Charles River's global network of scientific expertise and provide greater integration into CHDI's programs. "For two decades, we've been proud to be close partners of CHDI,"
3 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)